Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Rayzzeron Sep 15, 2017 2:35am
133 Views
Post# 26699471

RE:RE:Strong technical analysis

RE:RE:Strong technical analysistdon,

I believe LaserStock29 was the one that wrote that.

You can watch Dr Kulkarni's AGM presentation here: 
https://www.youtube.com/watch?v=3P_Pvq1kzVc&feature=youtu.be

@ 7:45 - the Overall Study Design is discussed explaining that all 9 patients will have follow up for 180 days post treatment.

@ 20:05 - the Schedule of Assessment is displayed. You will see that each patient is examined at 180 days. The examination includes among others things, urine cytology, CT scan, cytoscopy, and biopsy.

And don't miss this great quote from Dr Kulkarni @ 20:57:

"....out of 9 patients, it may be, that it works well in 2 or 3 only, and that would be phenomenal."


I'm looking forward to a phenonemal NR before the end of October. Maybe as early as October 24th.

JMO

Bullboard Posts